X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
Under the agreement, R-PHARM US has appointed Vector Pharma as exclusive distributor to import, use, market, sell and distribute Ixempra (ixabepilone) in the Middle East & North African territories.
Lead Product(s): Ixabepilone,Capecitabine
Therapeutic Area: Oncology Product Name: Ixempra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: R-Pharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 22, 2021
Details:
Allarity is currently conducting a DRP®-guided Phase 2 clinical trial to evaluate IXEMPRA® for the treatment of third-line metastatic breast cancer, with numerous trial sites planned in Europe, including Belgium, England, Denmark, Finland, Poland and Germany.
Lead Product(s): Ixabepilone
Therapeutic Area: Oncology Product Name: Ixempra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Details:
This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, stenoparib and dovitinib.
Lead Product(s): Ixabepilone
Therapeutic Area: Oncology Product Name: Ixempra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Negma
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Agreement February 11, 2021
Details:
This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, stenoparib and dovitinib.
Lead Product(s): Ixabepilone
Therapeutic Area: Oncology Product Name: Ixempra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Negma Group LTD
Deal Size: $1.2 million Upfront Cash: Undisclosed
Deal Type: Financing December 22, 2020
Details:
This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, stenoparib and dovitinib.
Lead Product(s): Ixabepilone
Therapeutic Area: Oncology Product Name: Ixempra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Negma Group
Deal Size: $11.7 million Upfront Cash: Undisclosed
Deal Type: Financing November 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
